focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics


BioLexa Platform™

Hoth owns the exclusive rights to develop the BioLexa Platform™ for all indications. The BioLexa Platform™ is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform™ combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.

We intend to explore the use of the BioLexa Platform™ for the treatment of atopic dermatitis, or eczema.

We also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. We believe that the BioLexa Platform’s™ ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.

Finally, we intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform‘s™ ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.

VNLG 152

Hoth has entered into a commercial evaluation sublicense and option agreement with the University of Maryland, Baltimore (“UMD”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”) for the use of VNLG 152 which provides a unique approach to achieve the therapeutic benefit of retinoid therapy while potentially circumventing the adverse events.

We intend to explore the use of VNLG 152 for the treatment of both acne and psoriasis


Hoth has exercised an exclusive license as well as a sponsored research agreement with the George Washington University to develop the use of WEG-232 for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.

AEA-loaded Z-pods™

Hoth entered a partnership Agreement with Zylö Therapeutics to develop Anandamide-loaded Z-pods™ for the treatment of CLE in North America. They are a Patent protected technology for a topical delivery system using xerogel-derived nanoparticles called Z-pods™. Scientists at the Albert Einstein College of Medicine, where the platform technology was originally developed, have demonstrated that topical administration with AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus. The work at Einstein supports the thesis that AEA-loaded Z-pods™:

    • improve drug penetration
    • prevent the development of skin lesions
    • improve skin histopathology
    • reduce macrophages and C3 accumulation
    • reduce inflammatory cytokine secretion by keratinocytes
    • have no deleterious effect on antibody levels

Exon Skipping

Hoth entered into an exclusive licensing agreement with North Carolina State University (NC State) to study NC State’s Exon Skipping Approach for Treating Allergic Diseases. This Exon Skipping Approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. During Dr. Cruse’s research, a new approach for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells was identified. These findings set a breakthrough for allergic diseases as they are driven by the activation of mast cells and the release of mediators in response to IgE-directed antigens.

We intend to explore the use of exon skipping for the treatment of undesirable steroid side effects who need an alternate treatment for asthma and other allergic diseases.

Genetic Marker License

Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.


Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.